Combined therapy with CD4 + CD25highCD127 − T regulatory cells and anti‐CD20 antibody in recent‐onset type 1 diabetes is superior to monotherapy: Randomized phase I/ II trial
Diabetes Obesity and Metabolism2022Vol. 24(8), pp. 1534–1543
Citations Over TimeTop 10% of 2022 papers
Maciej Zieliński, Magdalena Żalińska, Dorota Iwaszkiewicz‐Grześ, Mateusz Gliwiński, Matylda Hennig, Anna Jaźwińska‐Curyłło, Halla Kamińska, Justyna Sakowska, Anna Wołoszyn‐Durkiewicz, Radosław Owczuk, Wojciech Młynarski, Przemysława Jarosz‐Chobot, Artur Bossowski, Agnieszka Szadkowska, Janusz Siebert, Małgorzata Myśliwiec, Natalia Marek‐Trzonkowska, Piotr Trzonkowski
Abstract
Over 2 years, combined therapy with Tregs and rituximab was consistently superior to monotherapy in delaying T1DM progression in terms of C-peptide levels and the maintenance of remission.
Related Papers
- → Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab(2017)34 cited
- [Rituximab for managing refractory thrombotic thrombocytopenic purpura: a report of three cases].(2013)
- → A COMMON ERROR IN USING COMBINED TREATMENT WITH RITUXIMAB AND PLASMAPHERESIS (PP) TO PREVENT OR TREAT ANTIBODY MEDIATED REJECTION (AMR)(2020)
- [Long-term prognosis of patients with steroid-dependent nephrotic syndrome treated with rituximab].(2013)
- → Treatment: Rituximab(2018)